Diagnosis and treatment of prostate cancer: summary of NICE guidance.
作者信息
Graham John, Baker Mark, Macbeth Fergus, Titshall Victoria
机构信息
Taunton & Somerset NHS Foundation Trust, Musgrove Park Hospital, Taunton TA1 5DA.
出版信息
BMJ. 2008 Mar 15;336(7644):610-2. doi: 10.1136/bmj.39498.525706.AD.
Abstract
摘要
相似文献
1
Diagnosis and treatment of prostate cancer: summary of NICE guidance.前列腺癌的诊断与治疗：英国国家卫生与临床优化研究所指南摘要
BMJ. 2008 Mar 15;336(7644):610-2. doi: 10.1136/bmj.39498.525706.AD.
2
[Treatment of prostate cancer].[前列腺癌的治疗]
Orv Hetil. 2010 Apr 4;151(14):580-3. doi: 10.1556/OH.2010.28810.
3
Treatment options in hormone resistant prostate cancer.
Ann Oncol. 2002;13 Suppl 4:95-102. doi: 10.1093/annonc/mdf645.
4
[Prostate cancer: evolution of approach].
Vopr Onkol. 2009;55(2):241-9.
5
Current world literature.
Curr Opin Urol. 2013 Jul;23(4):377-88. doi: 10.1097/MOU.0b013e328362c382.
6
Management of relapsed prostatic carcinoma following primary treatment.
Eur Urol. 1993;24 Suppl 2:87-93. doi: 10.1159/000474398.
7
[Urology in 2011].
Rev Med Suisse. 2012 Jan 11;8(323):61-3.
8
[Combined treatment of metastatic hormone-resistant prostate cancer].[转移性激素抵抗性前列腺癌的联合治疗]
Vopr Onkol. 2009;55(4):477-9.
9
Update on the diagnosis and treatment of prostate cancer.
Curr Opin Oncol. 1998 May;10(3):244-52. doi: 10.1097/00001622-199805000-00012.
10
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.
J Urol. 2005 Jun;173(6):1966-7. doi: 10.1016/s0022-5347(05)60188-7.
引用本文的文献
1
NK Cell-Microbiota Interaction Biomarker Strategy: Advancing Prostate Cancer Management.自然杀伤细胞-微生物群相互作用生物标志物策略：推动前列腺癌管理
Biomolecules. 2025 Feb 13;15(2):273. doi: 10.3390/biom15020273.
2
The emerging role of Arid5a in cancer: A new target for tumors.干旱诱导蛋白5a（Arid5a）在癌症中的新作用：肿瘤的新靶点。
Genes Dis. 2022 Jan 25;10(3):813-824. doi: 10.1016/j.gendis.2021.12.012. eCollection 2023 May.
3
Recent Advances in the Role of Arid5a in Immune Diseases and Cancer.干旱诱导 5A 在免疫性疾病和癌症中的作用的最新进展。
Front Immunol. 2022 Jan 19;12:827611. doi: 10.3389/fimmu.2021.827611. eCollection 2021.
4
Systematic review and meta-analysis of the prognostic significance of microRNAs related to metastatic and EMT process among prostate cancer patients.系统评价和荟萃分析 miR-NAs 与前列腺癌患者转移和 EMT 过程相关的预后意义。
J Transl Med. 2021 Jan 7;19(1):28. doi: 10.1186/s12967-020-02644-x.
5
Effects of RNA Binding Proteins on the Prognosis and Malignant Progression in Prostate Cancer.RNA结合蛋白对前列腺癌预后及恶性进展的影响
Front Genet. 2020 Oct 20;11:591667. doi: 10.3389/fgene.2020.591667. eCollection 2020.
6
Effect of upregulation of DD3 on early detection and prognosis in prostate cancer.DD3上调对前列腺癌早期检测及预后的影响。
Transl Androl Urol. 2020 Aug;9(4):1550-1558. doi: 10.21037/tau-19-899.
7
Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review.去势抵抗性前列腺癌预后和预测生物标志物的临床意义：一项系统综述
Cancer Cell Int. 2020 Aug 26;20:409. doi: 10.1186/s12935-020-01508-0. eCollection 2020.
8
High mortality risk of prostate cancer patients in Asia and West Africa: A systematic review.亚洲和西非前列腺癌患者的高死亡风险：一项系统综述。
Avicenna J Med. 2020 Jul 3;10(3):93-101. doi: 10.4103/ajm.ajm_19_20. eCollection 2020 Jul-Sep.
9
Targeted beta therapy of prostate cancer with Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1).使用针对磷脂酰肌醇蛋白聚糖-1（GPC-1）的镥标记的米妥昔单抗®抗体对前列腺癌进行靶向β治疗。
EJNMMI Res. 2020 May 7;10(1):46. doi: 10.1186/s13550-020-00637-x.
10
Challenges in assessing solid tumor responses to immunotherapy.评估免疫疗法对实体瘤反应的挑战。
Cancer Gene Ther. 2020 Aug;27(7-8):528-538. doi: 10.1038/s41417-019-0155-1. Epub 2019 Dec 11.
Zotero 插件